Skip to main content

Compare Stocks

Date Range: 

 PMV PharmaceuticalsApplied Molecular TransportZealand Pharma A/STheravance BiopharmaIndivior
SymbolNASDAQ:PMVPNASDAQ:AMTINASDAQ:ZEALNASDAQ:TBPHOTCMKTS:INVVY
Price Information
Current Price$32.09$44.70$29.00$18.72$10.31
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.42.01.21.60.8
Analysis Score2.43.53.53.50.0
Community Score2.93.62.52.41.9
Dividend Score0.00.00.00.00.0
Ownership Score1.72.50.01.70.0
Earnings & Valuation Score0.00.60.00.61.9
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$38.00$68.75$43.00$31.33N/A
% Upside from Price Target18.42% upside53.80% upside48.28% upside67.38% upsideN/A
Trade Information
Market Cap$1.44 billion$1.58 billion$1.26 billion$1.22 billion$1.51 billion
BetaN/AN/A1.190.940.3
Average Volume163,194227,36011,822332,9048,310
Sales & Book Value
Annual RevenueN/AN/A$6.20 million$73.41 million$785 million
Price / SalesN/AN/A203.2316.651.93
CashflowN/AN/AN/AN/A$2.06 per share
Price / CashN/AN/AN/AN/A5.01
Book ValueN/AN/A$5.85 per share($3.94) per share$1.43 per share
Price / BookN/AN/A4.96-4.757.21
Profitability
Net IncomeN/A$-28,040,000.00$-85,670,000.00$-236,460,000.00$134 million
EPSN/AN/A($2.54)($4.25)$1.15
Trailing P/E Ratio0.000.00N/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A17.47
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A-214.31%-345.16%-31.93%
Return on Equity (ROE)N/AN/A-38.34%N/A-4.15%
Return on Assets (ROA)N/AN/A-30.40%-51.60%-0.26%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/A2.89%
Current RatioN/A19.39%6.76%4.32%1.82%
Quick RatioN/A19.39%6.51%4.32%1.69%
Ownership Information
Institutional Ownership Percentage69.72%51.99%4.32%80.41%N/A
Insider Ownership PercentageN/AN/AN/A5.90%N/A
Miscellaneous
Employees4480329359788
Shares Outstanding44.93 million35.25 million43.45 million65.28 million146.92 million
Next Earnings Date8/13/2021 (Estimated)8/10/2021 (Estimated)8/12/2021 (Estimated)8/5/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Drug Addiction Treatment Market 2026 Industry Specifications and Outlook 2021 |Indivior, Pfizer, Alkermes, Novartis, Mylan – Brockville Observer - Brockville ObserverDrug Addiction Treatment Market 2026 Industry Specifications and Outlook 2021 |Indivior, Pfizer, Alkermes, Novartis, Mylan – Brockville Observer - Brockville Observer
thebrockvilleobserver.ca - May 15 at 12:28 PM
Idaho among states to reach $300 million settlement with drug company Indivior - Idaho State JournalIdaho among states to reach $300 million settlement with drug company Indivior - Idaho State Journal
idahostatejournal.com - May 14 at 3:00 PM
WV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - The Logan BannerWV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - The Logan Banner
loganbanner.com - May 12 at 1:29 AM
WV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - Huntington Herald DispatchWV to get more than $5M in settlement over marketing of opioid withdrawal drug Suboxone - Huntington Herald Dispatch
herald-dispatch.com - May 9 at 12:43 AM
NJ Gets Share Of $300M Opioid Treatment Settlement - Patch.comNJ Gets Share Of $300M Opioid Treatment Settlement - Patch.com
patch.com - May 7 at 6:28 PM
ATTORNEY GENERAL SCHMITT ANNOUNCES SETTLEMENT WITH INDIVIOR OVER FALSE MARKETING RELATED TO SUBOXONE - kmmo.comATTORNEY GENERAL SCHMITT ANNOUNCES SETTLEMENT WITH INDIVIOR OVER FALSE MARKETING RELATED TO SUBOXONE - kmmo.com
kmmo.com - May 7 at 1:16 PM
Healey Secures $6.65 Million from Drug Company for False Marketing - CapeCod.com NewsHealey Secures $6.65 Million from Drug Company for False Marketing - CapeCod.com News
capecod.com - May 7 at 8:16 AM
Rio Tinto and Indivior investors revolt over executive pay awards - The TimesRio Tinto and Indivior investors revolt over executive pay awards - The Times
thetimes.co.uk - May 7 at 8:16 AM
Indivior hit by investor rebellion over payout to former CEO - NasdaqIndivior hit by investor rebellion over payout to former CEO - Nasdaq
nasdaq.com - May 6 at 7:14 PM
UPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs - MorningstarUPDATE: Pay comes under spotlight at BAE, Indivior and Rio Tinto AGMs - Morningstar
morningstar.co.uk - May 6 at 2:14 PM
Attorney General Schmitt Announces Settlement with Indivior Over False Marketing Related to Suboxone - EIN NewsAttorney General Schmitt Announces Settlement with Indivior Over False Marketing Related to Suboxone - EIN News
einnews.com - May 6 at 2:14 PM
Thursday newspaper round-up: Covid contracts, Indivior, KPMG, Glaxo - ShareCastThursday newspaper round-up: Covid contracts, Indivior, KPMG, Glaxo - ShareCast
sharecast.com - May 6 at 3:39 AM
Attorney General Morrisey reaches settlement involving opioid withdrawal drug - WBOY.comAttorney General Morrisey reaches settlement involving opioid withdrawal drug - WBOY.com
wboy.com - May 5 at 7:38 AM
Momentum investing with Indivior (LON:INDV) - StockopediaMomentum investing with Indivior (LON:INDV) - Stockopedia
stockopedia.com - May 5 at 7:38 AM
W.Va. AG announces settlement over false claims - Parkersburg NewsW.Va. AG announces settlement over false claims - Parkersburg News
newsandsentinel.com - May 5 at 1:36 AM
Indivior faces shareholder ire over bonus for imprisoned ex-CEOIndivior faces shareholder ire over bonus for imprisoned ex-CEO
finance.yahoo.com - May 5 at 1:36 AM
Study: 1 in 5 Pharmacies Blocks Access to Addiction Treatment Buprenorphine - Pharmacy TimesStudy: 1 in 5 Pharmacies Blocks Access to Addiction Treatment Buprenorphine - Pharmacy Times
pharmacytimes.com - May 3 at 1:22 PM
WV to receive more than $5.2M in pharmaceutical company settlement - WOWK 13 NewsWV to receive more than $5.2M in pharmaceutical company settlement - WOWK 13 News
wowktv.com - May 3 at 1:22 PM
Addex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021 - StreetInsider.comAddex Therapeutics to Release Q1 2021 Financial Results and Host Conference Call on May 5, 2021 - StreetInsider.com
streetinsider.com - May 3 at 8:21 AM
Indivior PLCs (INVVY) CEO Mark Crossley on Q1 2021 Results - Earnings Call Transcript - Seeking AlphaIndivior PLC's (INVVY) CEO Mark Crossley on Q1 2021 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 1 at 1:35 PM
Md AG Announces $300 Million Settlement with Drug Distributor - WCBC RadioMd AG Announces $300 Million Settlement with Drug Distributor - WCBC Radio
wcbcradio.com - May 1 at 8:35 AM
AG Cameron announces $300 million multistate settlement with Indivior - ABC 36 News - WTVQAG Cameron announces $300 million multistate settlement with Indivior - ABC 36 News - WTVQ
wtvq.com - April 30 at 7:47 PM
Drug Addiction Treatment Market Insight and Forecast to 2026 | Indivior, Pfizer, Alkermes, Novartis – Good News Gum - Good News GumDrug Addiction Treatment Market Insight and Forecast to 2026 | Indivior, Pfizer, Alkermes, Novartis – Good News Gum - Good News Gum
goodnewsgum.com - April 30 at 2:46 PM
Attorney General Moody Secures $300 Million Following Investigation into Improper Marketing and Sale of Suboxone - EIN NewsAttorney General Moody Secures $300 Million Following Investigation into Improper Marketing and Sale of Suboxone - EIN News
einnews.com - April 30 at 2:46 PM
Indivior swings into profit - Capital.comIndivior swings into profit - Capital.com
capital.com - April 29 at 9:34 AM
DateCompanyBrokerageAction
10/20/2020PMV PharmaceuticalsEvercore ISIInitiated Coverage
10/20/2020PMV PharmaceuticalsBank of AmericaInitiated Coverage
10/20/2020PMV PharmaceuticalsThe Goldman Sachs GroupInitiated Coverage
10/20/2020PMV PharmaceuticalsCowenInitiated Coverage
3/23/2021Applied Molecular TransportJefferies Financial GroupBoost Price Target
3/23/2021Applied Molecular TransportJMP SecuritiesInitiated Coverage
2/25/2021Applied Molecular TransportSVB LeerinkBoost Price Target
11/13/2020Zealand Pharma A/SMorgan StanleyLower Price Target
8/13/2020Zealand Pharma A/SNeedham & Company LLCInitiated Coverage
9/19/2019Zealand Pharma A/SGuggenheimInitiated Coverage
11/6/2020Theravance BiopharmaHC WainwrightReiterated Rating
8/7/2020Theravance BiopharmaPiper SandlerLower Price Target
7/7/2020Theravance BiopharmaJPMorgan Chase & Co.Initiated Coverage
7/27/2020IndiviorCitigroupUpgrade
7/27/2020IndiviorStifel NicolausUpgrade
(Data available from 5/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.